Therapeutics Related News

Cellectis Patent Encompassing Broad Uses of Gene Editing Technologies Maintained by USPTO

May 10, 2017 – New York (N.Y.) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that U.S. patent 8,921,332, which claims the use of chimeric restriction [...]

By | May 12th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Genome Editing Patent in Europe

BERKELEY, CA – May 10, 2017 – Caribou Biosciences, Inc., a leading genome engineering company, announced today that the European Patent Office (EPO) has granted a broad CRISPR-Cas9 genome editing patent to The Regents of the University of California, the [...]

By | May 12th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Caribou Biosciences and DuPont Pioneer Develop New Method to Comprehensively Map the Off-Target Activity of CRISPR-Cas9 Across Entire Genomes

BERKELEY, Calif. and JOHNSTON, Iowa – May 1, 2017 – Caribou Biosciences, Inc., a leading company in CRISPR-Cas genome engineering, and DuPont Pioneer today announced the Nature Methods publication describing SITE-Seq, a new method for comprehensively mapping CRISPR-Cas9 cleavage sites [...]

By | May 2nd, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio

BASEL, Switzerland and CAMBRIDGE, Mass. and DURHAM, N.C., April 17, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer [...]

By | April 18th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Platform Empowered by Membrane-Bound IL-15 Under RheoSwitch Therapeutic System Control

Germantown, MD, and Boston, MA, April 3, 2017 - Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ZIOPHARM Oncology (NASDAQ: ZIOP), a biopharmaceutical company [...]

By | April 3rd, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Cell Design Labs Announces Issuance of Broad Patent for Programmable Car-T Cells to Treat Cancer and Other Diseases

SAN FRANCISCO, Calif. – March 15, 2017 – Cell Design Labs, Inc. today announced the issuance of U.S. Patent No. 9,587,020, entitled, “Chimeric Antigen Receptor and Methods of Use Thereof.” This patent, issued to UC San Francisco (UCSF) and exclusively [...]

By | March 26th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|